Holen Sie sich die Stockscreener-App
4.72
4.01%
-0.27
Schlusskurs vom Vortag:
$4.99
Offen:
$4.82
24-Stunden-Volumen:
40,641
Relative Volume:
0.13
Marktkapitalisierung:
$88.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.20%
1M Leistung:
-27.86%
6M Leistung:
-17.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.67
$4.99
1-Wochen-Bereich:
$4.67
$5.45
52-Wochen-Spanne:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Firmenname
Kalaris Therapeutics Inc
Sektor
Branche
Telefon
650-249-2727
Adresse
628 MIDDLEFIELD ROAD, PALO ALTO
Vergleichen Sie KLRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.72 | 93.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.22 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.73 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.59 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-23 | Fortgesetzt | Piper Sandler | Neutral |
| 2025-05-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
Kalaris Therapeutics Inc Aktie (KLRS) Neueste Nachrichten
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Citizens Jmp Begins Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - MarketBeat
What to expect from Kalaris Therapeutics Inc. in the next 30 daysLong Setup & Consistent Growth Stock Picks - newser.com
How resilient is Kalaris Therapeutics Inc. stock in market downturnsGap Up & High Accuracy Investment Entry Signals - newser.com
Does Kalaris Therapeutics Inc. qualify in momentum factor screeningWeekly Investment Report & Verified Stock Trade Ideas - newser.com
What MACD and RSI say about Kalaris Therapeutics Inc.Weekly Trend Recap & Daily Profit Maximizing Trade Tips - newser.com
Analyzing Kalaris Therapeutics Inc. with risk reward ratio chartsMarket Trend Report & Weekly Stock Breakout Alerts - newser.com
Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer - VisionMonday.com
Tools to assess Kalaris Therapeutics Inc.’s risk profile2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Identifying reversal signals in Kalaris Therapeutics Inc.Bull Run & Growth-Oriented Investment Plans - newser.com
Citizens Initiates Coverage of Kalaris Therapeutics (KLRS) with Market Outperform Recommendation - Nasdaq
Kalaris Therapeutics appoints Matthew Gall as chief financial officer By Investing.com - Investing.com Nigeria
KLRS Sees New Analyst Rating: Citizens Initiates with Market Out - GuruFocus
Can trapped investors hope for a rebound in Kalaris Therapeutics Inc.Bull Run & Real-Time Chart Breakout Alerts - newser.com
Will Kalaris Therapeutics Inc. outperform the marketMarket Trend Summary & Risk Managed Investment Signals - newser.com
How Kalaris Therapeutics Inc. stock performs in rate cut cycles2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Kalaris Therapeutics Appoints New CFO Matthew Gall - TipRanks
Kalaris Therapeutics appoints Matthew Gall as chief financial officer - Investing.com
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - The Manila Times
Kalaris (KLRS) names Matthew Gall CFO amid Phase 1b/2 nAMD study enrollment - Stock Titan
What’s next for Kalaris Therapeutics Inc. stock price2025 Short Interest & Target Return Focused Stock Picks - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target By Investing.com - Investing.com South Africa
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target - Investing.com
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Declines By 40.5% - MarketBeat
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Kalaris Therapeutics Inc. stock outlook for YEAR2025 Performance Recap & Community Verified Watchlist Alerts - newser.com
Finanzdaten der Kalaris Therapeutics Inc-Aktie (KLRS)
Es liegen keine Finanzdaten für Kalaris Therapeutics Inc (KLRS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):